Medical devices industry venture financing deals in Q2 2019 total $2.77bn globally

17 July 2019 (Last Updated July 17th, 2019 07:03)

Medical devices industry venture financing deals in Q2 2019 total $2.77bn globally

Total medical devices industry venture financing deals in Q2 2019 worth $2.77bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 22.9% over the previous quarter and a rise of 22.9% when compared with the last four-quarter average, which stood at $2.26bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.07bn. At the country level, the US topped the list in terms of deal value at $1.96bn.

In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of venture financing deals activity in Q2 2019 was the US with 176 deals, followed by China with 17 and Canada with 13.

In 2019, as of the end of Q2 2019, medical devices venture financing deals worth $5.03bn were announced globally, marking a decrease of 2.9% year on year.

Medical devices industry venture financing deals in Q2 2019: Top deals

The top five medical devices industry venture financing deals accounted for 20.4% of the overall value during Q2 2019.

The combined value of the top five medical devices industry venture financing deals stood at $565m, against the overall value of $2.77bn recorded for the quarter. The top announced medical devices industry venture financing deal tracked by GlobalData in Q2 2019 was Gold Stone Investment, Green Pine Capital Partners and Shanghai Orient Securities Capital Investment’s $200m venture financing of MGI Tech.

In second place was the $110m venture financing of Thrive Earlier Detection by Biomatics Capital Partners, BlueCross BlueShield Venture Partners, Camden Partners Holdings, Casdin Capital, Cowin Venture Capital, Exact Sciences, Gamma3, Section 32, Invus Group and Third Rock Ventures and in third place was 8VC, Advent Venture Partners, Deerfield ManagementLP, GE Ventures, Opaleye Management, Orbimed Advisors, Pura Vida Investments and Xeraya Capital Sdn’s $100m venture financing of Acutus Medical.

The $82m venture financing of Tissuetech by Ballast Point Ventures and EW Healthcare Partners and Andreessen Horowitz, Cigna Ventures, Civilization Ventures, Kaiser Permanente Ventures, Norwest Venture Partners XII, Providence Ventures, Sanofi Ventures, USVP ManagementLlc and Wellington ManagementLLP’s venture financing of Omada Health for $73m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.